Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies
Abstract Introduction Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). Methods A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 mg once daily for 12 weeks on primary safety and pharma...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
Subjects: | |
Online Access: | https://doi.org/10.1002/trc2.12296 |